Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis

Objective  Our objectives were to develop the population pharmacokinetic (PK) for pertuzumab and examine the variability of steady-state trough serum concentrations (CSS,trough) and exposure after fixed, body-weight-based, or body-surface area (BSA)-based dosing methods in cancer patients.